Year-end report October – December 2020
Curasight A/S (“Curasight” or “the Company”) hereby publishes the year-end report for the period October 1 – December 31, 2020. The year-end report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.
Curasight’s CEO Ulrich Krasilnikoff comments:
“The initiation of a pre-clinical therapy study in Glioblastoma (brain cancer) during the fourth quarter marks the beginning of developing Curasight’s therapy method into a clinically useful method. Glioblastoma is challenging to treat, and there has essentially been no significant improvement in patients’ survival over the past 15 years. With our targeted radionuclide method (uTREAT®) we expect more gentle therapy with little harm to normal tissue compared to external radiation therapy. Curasight has made significant progress in advancing the development of its uPAR Theranostics platform, which combines radiation therapy for cancer uTREAT® (therapy) with uTRACE® (diagnostics). Combining these two methods makes it possible to detect and treat cancer and metastases in a more gentle and efficient way than today’s method of external radiation therapy. During the financial year the investigator-initiated clinical phase IIb trial in prostate cancer was completed. The results and knowledge obtained from the investigator-initiated diagnostic trials will form the basis for selecting relevant cancer indications and increase the likelihood of a successful progress with uTREAT®.”
Fourth quarter 2020
- Net sales amounted to 0 (0) DKK
- Operating profit/loss amounted to -4,425,970 (-301,108) DKK
- Profit/loss before taxes amounted to -4,767,110 (-675,702) DKK
- Profit/loss for the period amounted to -4,767,178 (-527,048) DKK
- Total assets amounted to 63,105,845 (22,542,380) DKK
- Equity ratio amounted to 93.7 (80.0)
- Earnings per share amounted to -0.27 (-0.04*)
January – December 2020
- Net sales amounted to 0 (0) DKK
- Operating profit/loss amounted to -4,791,150 (-738,582) DKK
- Profit/loss before taxes amounted to -5,773,575 (-1,711,630) DKK
- Profit/loss for the year amounted to -5,552,201 (-1,335,072) DKK
- Total assets amounted to 63,105,845 (22,542,380) DKK
- Equity ratio amounted to 93.7 (80.0)
- Earnings per share amounted to -0.32 (-0.10*)
* Nom. Value per share changed in 2019 from DKK 1.00 to DKK 0.05
Highlights during the period
On October 7, Curasight announced that the Company had entered into an expansion of the agreement with TRT Innovations ApS (“TRT Innovations”), which ensures the right for the Company to broaden its activities within targeted radionuclide therapy in cancer.
October 8 was the first day of trading with Curasight’s shares and warrants of series TO 1. The shares are traded under the ticker “CURAS” with ISIN DK0061295797 and Curasight’s warrants of series TO 1 are traded under the ticker ”CURAS TO 1” with ISIN DK0061408747.
On October 22, Curasight announced that the Company’s Canadian patent application CA 2,903,261 was ready for allowance and the patent will be issued. This patent application relates to Curasight’s imaging technology relating to uTRACE® (imaging agent 68Ga-NOTA-AE105) and uses thereof until 2034.
On November 13, Curasight announced that the Company had initiated the pre-clinical study of uPAR targeted radionuclide therapy (uTREAT®) in brain cancer and signed an agreement with the Danish CRO Minerva Imaging A/S (“Minerva Imaging”), to conduct the pre-clinical study.
On December 16, Curasight announced that the Japan Patent Office had issued a notice of allowance confirming that the Japanese Patent Application no. 2019-005811 regarding 177-Lu Labeled peptide conjugate for site specific uPAR-targeting will be granted. The patent application relates to Curasight’s therapeutic technology uTREAT® and uses thereof.
On December 21, Announcement that the Phase II investigator-initiated study in prostate cancer is to be published in an upcoming issue of the Journal of Nuclear Medicine.
Highlights after the period
On February 8, Curasight announced that the United States Patent and Trademark Office had issued a notice
of allowance confirming that the United States Patent Application no. 14/399,820 regarding 177-Lu Labeled
peptide conjugate for site specific uPAR-targeting will be granted.
For more information regarding Curasight, please contact:
Ulrich Krasilnikoff, CEO
Phone: +45 22 83 01 60
E-mail: uk@curasight.com
Curasight is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology provides improved diagnosis and risk stratification in multiple cancer types.